LIB Therapeutics is a privately held, late-stage biopharmaceutical company dedicated to bringing novel, safe and convenient subcutaneous and oral PCSK9 inhibitors to the millions of patients at very high and high-risk of cardiovascular disease (CVD), and the 30 million with familial hypercholesterolemia (FH), who require additional large reductions